After the great success of Viagra, pharmaceutical companies have set a new goal: the "female Viagra", i.e. a pill for hypoactive sexual desire disorder (HSDD), the most commonly diagnosed female sexual dysfunction. Each subsequent proposal for the treatment of low desire showed the process of disease mongering in all its glory and simultaneous attempts to strengthen the hypotheses about its biological basis: depending of the drug manufacturer HSDD was supposed to be due to androgen deficiency, disordered pelvic blood circulation, or neurotransmitters imbalance.